Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043548 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
A Phase 2 study of Dermatomyositis and Polymyositis, sponsored by Chester Oddis.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT02043548: Completed Phase 2 study of Dermatomyositis and Polymyositis, sponsored by Chester Oddis.
NCT02043548 is a Phase 2 study of Dermatomyositis and Polymyositis that has completed, run by Chester Oddis. The registered enrollment target is 36 participants, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02043548, a Phase 2 study of Dermatomyositis and Polymyositis, has completed, sponsored by Chester Oddis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this multi-center pilot study is to determine if the drug tocilizumab (Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM) and dermatomyositis (DM).
Primary Outcome
The total improvement score was calculated by adding the improvement scores of all six core set measures based on 2016 American College of Rheumatology (ACR)/European League Against Rheumatism(EULAR) myositis response criteria. The minimum and maximum values of the average Total Improvement Scores are 0 and 100; The minimum and maximum values of the average Total Improvement Scores of our included patients are 5.0 and 67.1; The higher scores mean a better outcome.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tocilizumab
Study Locations (7)
California
- Cedars Sinai Medical Center - Los Angeles
Kansas
- University of Kansas Medical Center - Kansas City
Minnesota
- Mayo Clinic - Rochester
New York
- North Shore Long Island Jewish Center - Great Neck
Pennsylvania
- University of Pittsburgh - Pittsburgh
Tennessee
- Vanderbilt University - Nashville
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-10-01 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 2 |
What the finished NCT02043548 record still lists
NCT02043548 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Dermatomyositis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT02043548 lists 7 locations in 7 states (California, Kansas, Minnesota).
Frequently Asked Questions
What is clinical trial NCT02043548 about?
NCT02043548 is a clinical study titled "Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis". The purpose of this multi-center pilot study is to determine if the drug tocilizumab (Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM) and dermatomyositis (DM).
What is the current status of trial NCT02043548?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-10-01. Estimated completion is 2019-07-31.
What conditions does trial NCT02043548 study?
This clinical trial studies the following conditions: Dermatomyositis, Polymyositis.
What interventions are being tested in trial NCT02043548?
The interventions under investigation include: placebo (DRUG), tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02043548?
This trial is sponsored by Chester Oddis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02043548 being conducted?
This trial has 7 study locations across California, Kansas, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02043548's enrollment target sits among peer trials
36 14th of 19 higher than 6 of 19 other Dermatomyositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatomyositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RECRUITING · Phase 2
-
Intralesional Injection of STS in Treatment of Calcinosis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI